Answer a few questions using Lilly Trial Connect to find which Lilly trials may be the best fit for you or your loved one.
Answer a few questions using Lilly Trial Connect to find which Lilly trials may be the best fit for you or your loved one.

Find a Lilly Clinical Trial

7  Enrolling
20  Total Trials
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (PIKASSO-01)
Enrolling
Conditions: Breast Cancer, Advanced Solid Tumors
Trial Name
PIKASSO-01
Drugs: LOXO-783
Age
≥18 years
Phase
I
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Enrolling
Conditions: Lung Cancer, Advanced Solid Tumors
Drugs: LY3537982, Abemaciclib, Pembrolizumab, LY3295668, Cetuximab
Age
≥18 years
Phase
I
A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3
Enrolling
Conditions: Bladder Cancer, Advanced Solid Tumors
Drugs: LOX-24350 / LOXO-435, Pembrolizumab
Age
≥18 years
Phase
I
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
Enrolling
Conditions: Solid tumors
Drugs: LY4101174
Age
≥18 years
Phase
I
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Enrolling
Conditions: Lung Cancer, Colorectal Cancer, Endometrial Cancer, Ovarian Cancer, Pancreatic Cancer, Triple Negative Breast Cancer, Uterine Cancer
Drugs: LY4170156
Age
≥18 years
Phase
I
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (NEXUS-01)
Enrolling
Conditions: Solid tumors
Trial Name
NEXUS-01
Drugs: LY4052031
Age
≥18 years
Phase
I
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer (EMBER-4)
Enrolling
Conditions: Breast Cancer
Trial Name
EMBER-4
Drugs: Anastrozole, Exemestane, Imlunestrant, Letrozole, Tamoxifen
Age
≥18 years
Phase
III

Lilly Trial Alerts

Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.
13 
Completed Enrollment
20  Total Trials
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Completed Enrollment
Conditions: Advanced Solid Tumor
Drugs: LY3410738
Age
≥18 years
Phase
I
A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment (JUVE-BASIS)
Completed Enrollment
Conditions: Lung Cancer, Thyroid Cancer and other Solid Tumors
Trial Name
JUVE-BASIS
Drugs: LOXO-260
Age
≥12 years
Phase
I
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Adv...
Completed Enrollment
Conditions: Breast Cancer
Trial Name
EMBER-3
Drugs: LY3484356, Exemestane, Fulvestrant, Imlunestrant, Abemaciclib
Age
≥18 years
Phase
III
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (EMBER)
Completed Enrollment
Conditions: Breast Cancer, Endometrial Cancer
Trial Name
EMBER
Drugs: LY3484356, Abemaciclib
Age
≥18 years
Phase
I
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer (postMONARCH)
Completed Enrollment
Conditions: Breast Cancer
Trial Name
postMONARCH
Drugs: Abemaciclib, Fulvestrant
Age
≥18 years
Phase
III
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE)
Completed Enrollment
Conditions: Breast Cancer
Trial Name
monarchE
Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Age
≥18 years
Phase
III
A Study of LY3200882 in Participants With Solid Tumors
Completed Enrollment
Conditions: Advanced Solid Tumor
Drugs: LY3200882
Age
≥18 years
Phase
I
A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer (Next MONARCH 1)
Completed Enrollment
Conditions: Breast Cancer
Trial Name
Next MONARCH 1
Drugs: Abemaciclib, Tamoxifen, Prophylactic Loperamide
Age
≥18 years
Phase
II
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors...
Completed Enrollment
Conditions: Advanced Solid Tumors
Drugs: Abemaciclib, Irinotecan, Temozolomide, Dinutuximab and GM-CSF
Age
≤21 years
Phase
II
A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (PACT)
Completed Enrollment
Conditions: Advanced Solid Tumor
Trial Name
PACT
Drugs: Ramucirumab, Abemaciclib, Merestinib, LY3300054
Age
≥18 years
Phase
I
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer (MONARCH plus)
Completed Enrollment
Conditions: Breast Cancer
Trial Name
MONARCH plus
Drugs: Abemaciclib, Anastrozole, Letrozole, Fulvestrant
Age
≥18 years
Phase
III
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Completed Enrollment
Conditions: Breast Cancer
Drugs: LY2835219, Letrozole, Anastrozole, Tamoxifen, Exemestane
Age
≥18 years
Phase
I
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
Completed Enrollment
Conditions: Breast Cancer, Non-Small Cell Lung Cancer
Drugs: Abemaciclib, Pembrolizumab
Age
≥18 years
Phase
I